Burkitt Lymphoma · line 1 · eviQ proven-CNS R-CODOX-M / R-IVAC reference for specialist review
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-CODOX-IVAC-PROVEN-CNS |
| ID | IND-BURKITT-1L-CODOX-IVAC-PROVEN-CNS |
|---|---|
| Type | Indication |
| Status | pending_clinical_signoff |
| Diseases | DIS-BURKITT |
| Sources | SRC-EVIQ-BURKITT-CNS-CODOX-4492 SRC-EVIQ-BURKITT-CNS-IVAC-4493 |
Notes
No individualized or clinically approved treatment recommendation. Age/fitness, diagnosis/biomarkers, HIV/immune status, organ function and toxicity require separate assessment. No efficacy or availability estimates asserted.
Used By
Algorithms
ALGO-BURKITT-1L- ALGO-BURKITT-1L